Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing selonabant, a cannabinoid receptor type-1 (CB1) antagonist designed to treat cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication (ACI). The company’s lead product candidate, available in oral and intravenous formulations, aims to rapidly reverse cannabis-induced symptoms. Anebulo targets emergency departments and vulnerable populations, particularly pediatric patients, addressing a growing unmet medical need in the U.S. cannabis market.
This description was generated via AI from an annual report. Updated about 1 year ago.